| 9.83 0.39 (4.13%) | 05-05 11:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.7 |
1-year : | 12.7 |
| Resists | First : | 10.02 |
Second : | 10.88 |
| Pivot price | 9.58 |
|||
| Supports | First : | 8.64 |
Second : | 7.18 |
| MAs | MA(5) : | 9.18 |
MA(20) : | 9.66  |
| MA(100) : | 9 |
MA(250) : | 7.74 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.2 |
D(3) : | 24.3 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 12.34 | Low : | 3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FDMT ] has closed below upper band by 41.5%. Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.56 - 9.6 | 9.6 - 9.64 |
| Low: | 9.01 - 9.05 | 9.05 - 9.09 |
| Close: | 9.37 - 9.44 | 9.44 - 9.52 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Mon, 04 May 2026
4DMT management to present at BofA, RBC healthcare conferences - Stock Titan
Tue, 28 Apr 2026
[ARS] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Tue, 28 Apr 2026
Board moves key votes at 4D Molecular Therapeutics (NASDAQ: FDMT) 2026 meeting - Stock Titan
Sat, 18 Apr 2026
4DMT Announces New Employment Inducement Grants - Sahm
Wed, 18 Mar 2026
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Fri, 27 Feb 2026
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -54 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.227e+007 (%) |
| Held by Institutions | 3.526e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0729e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.43 |
| Profit Margin | -164.5 % |
| Operating Margin | 17.4 % |
| Return on Assets (ttm) | -17.4 % |
| Return on Equity (ttm) | -27.6 % |
| Qtrly Rev. Growth | 8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.5165e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -4.03 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.152e+007 |
| Forward Dividend | 1.04e+007 |
| Dividend Yield | 118344000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|